High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.
暂无分享,去创建一个
Ekaterina S Jordanova | J. M. van der Hulst | Sjoerd H van der Burg | S. H. van der Burg | E. Jordanova | G. Fleuren | G. Kenter | R. Offringa | J. Drijfhout | C. Melief | Gert Jan Fleuren | S. Piersma | K. Kwappenberg | Jan W Drijfhout | Rienk Offringa | Cornelis J M Melief | Gemma G Kenter | Sytse J Piersma | Mariëtte I E van Poelgeest | Kitty M C Kwappenberg | Jeanette M van der Hulst | M. V. van Poelgeest | J. van der Hulst | M. van Poelgeest | Sytse J. Piersma | Ekaterina Jordanova
[1] C. Yuan,et al. Correlation of three-dimensional tumor volumetry with cervical cancer prognostic parameters. , 2002, European journal of gynaecological oncology.
[2] J. M. van der Hulst,et al. Rapid enrichment of human papillomavirus (HPV)‐specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer , 2005, International journal of cancer.
[3] L. Borysiewicz,et al. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. , 1997, Cancer research.
[4] G. Kenter,et al. The case for completing the lymphadenectomy when positive lymph nodes are found during radical hysterectomy for cervical carcinoma , 2000, Acta obstetricia et gynecologica Scandinavica.
[5] S. H. van der Burg,et al. Detection of human papillomavirus type 18 E6 and E7‐specific CD4+ T‐helper 1 immunity in relation to health versus disease , 2006, International journal of cancer.
[6] S. H. van der Burg,et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] H. Hausen. Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.
[8] H. Putter,et al. A basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancer , 2003, Cancer Immunology, Immunotherapy.
[9] J. M. van der Hulst,et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. , 2003, Cancer research.
[10] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[11] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] Harald zur Hausen,et al. Papillomavirus infections — a major cause of human cancers , 1996 .
[13] J. M. van der Hulst,et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. , 2002, Cancer research.
[14] E. Sabo,et al. Intratumoral CD8+ T Lymphocytes as a Prognostic Factor of Survival in Endometrial Carcinoma , 2004, Clinical Cancer Research.
[15] A. Sette,et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. , 1996, Cancer research.
[16] J. Drijfhout,et al. Least Four Unrelated + CD 4 Is Processed and Presented to HIV-Specific Epitope in HIV-1 Reverse Transcriptase That Identification of a Conserved Universal Th , 1998 .
[17] A. Mori,et al. Increased Intratumor Vα24-Positive Natural Killer T Cells: A Prognostic Factor for Primary Colorectal Carcinomas , 2005, Clinical Cancer Research.
[18] N. Singh,et al. Histopathologic parameters of prognosis in cervical cancer – a review , 2004, International Journal of Gynecologic Cancer.
[19] S. Bellone,et al. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. , 2003, Gynecologic oncology.
[20] G. Fleuren,et al. Isolation and characterization of tumor‐infiltrating lymphocytes from cervical carcinoma , 1994, International journal of cancer.
[21] H. Pilch,et al. Human Papillomavirus Type 33 E7 Peptides Presented by HLA-DR*0402 to Tumor-Infiltrating T Cells in Cervical Cancer , 2000, Journal of Virology.
[22] J. Hjelmborg,et al. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells , 2003, Cancer Immunology, Immunotherapy.
[23] H. Chao,et al. Lymphocyte-infiltrated FIGO Stage IIB squamous cell carcinoma of the cervix is a prominent factor for disease-free survival. , 1999, European journal of gynaecological oncology.
[24] S. H. van der Burg,et al. The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. , 2002, Virus research.
[25] S. Wilczynski,et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] J. M. van der Hulst,et al. Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 , 2004, Cancer Research.
[27] F. X. Bosch,et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.
[28] A. Zwinderman,et al. Adjuvant radiotherapy following radical hysterectomy for patients with early-stage cervical carcinoma (1984-1996). , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[29] S. Quezada,et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.
[30] S. H. van der Burg,et al. Natural T‐helper immunity against human papillomavirus type 16 (hpv16) e7–derived peptide epitopes in patients with hpv16‐positive cervical lesions: Identification of 3 human leukocyte antigen class ii–restricted epitopes , 2001, International journal of cancer.
[31] F. X. Bosch,et al. Human papillomavirus and cervical cancer , 1989 .
[32] H. Putter,et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis , 2004, Laboratory Investigation.
[33] P. Shepherd,et al. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. , 1996, The Journal of general virology.
[34] V. Moreno,et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.
[35] I. Frazer,et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. , 2004, Vaccine.
[36] S. Stacey,et al. Human papillomavirus type 16 E6/E7‐specific cytotoxic T lymphocytes in women with cervical neoplasia , 2000, International journal of cancer.
[37] H. Fiegl,et al. The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer , 2005, Clinical Cancer Research.
[38] Julian Peto,et al. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .
[39] Cornelis J H van de Velde,et al. Four‐color staining combining fluorescence and brightfield microscopy for simultaneous immune cell phenotyping and localization in tumor tissue sections , 2005, Microscopy research and technique.
[40] H. Kitchener,et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. , 2003, Cancer research.
[41] V. Calvez,et al. CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. , 1998, International immunology.
[42] B. Seliger,et al. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. , 1999, Journal of immunology.
[43] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[44] G. Thomas. Adjuvant therapy after primary surgery for stage I-IIA carcinoma of the cervix. , 1996, Journal of the National Cancer Institute. Monographs.
[45] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[46] W. Quint,et al. Human papillomavirus detection in paraffin-embedded cervical carcinomas and metastases of the carcinomas by the polymerase chain reaction. , 1989, The American journal of pathology.
[47] B. Delahunt,et al. Infiltration By Immunocompetent Cells In Early Stage Invasive Carcinoma Of The Uterine Cervix: A prognostic study , 1996, Pathology.
[48] Thomas Gm. Adjuvant therapy after primary surgery for stage I-IIA carcinoma of the cervix. , 1996 .
[49] S. H. van der Burg,et al. Magnitude and polarization of P53‐specific T‐helper immunity in connection to leukocyte infiltration of colorectal tumors , 2003, International journal of cancer.
[50] S. H. van der Burg,et al. Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination , 2004, Clinical Cancer Research.